NICE Guidance - July 2023
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of July 2023. This month there is one technology appraisal and one clinical guideline that impact upon primary care.
The Semaglutide for managing overweight and obesity in young people aged 12 to 17 years technology appraisal has been terminated. At this time, NICE is unable to make a recommendation about the use in the NHS of semaglutide for managing overweight and obesity in young people aged 12 to 17 years. The manufacturer has confirmed that it does not intend to make an evidence submission for the appraisal. In the absence of any recommendation this drug should not be used for this indication in the specified age group.
The Obesity: identification, assessment and management guideline has been updated. It covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults. The update has reviewed the evidence on bariatric surgery and updated the recommendations made for when to refer adults for assessment for bariatric surgery.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « Drug Safety Update - July 2023 | CKS Updates - July 2023 » |
Leave a Comment